CARDIFF ONCOLOGY INC

CRDF NASDAQ

UnitedTrading

CRDF is at a double support currently. Could be a really good buy in point here. Don't be afraid to buy in small portions. 1st target is $15 to see if we get past that natural resistance. Options could be a possible way to go as well. Also, don't forget Cardiff is speaking at a virtual presentation on February 17th.

CubMon

CRDF = Bullish (Toro) Inn: 15.50 pTs: 17, 19, 21

runNgun

WILL BE WATCHING PRE MARKET FOR MY ENTRY

shkspr

NASDAQ:CRDF Possible Scenario: LONG Evidence: Price Action, Reversal Candlestick, Unusual option activities for Feb 19 at 20$ TP1: 15$, TP2: 19$ Mental Stop loss: 10.80$, risk reward ratio is 5 to 1 This is my idea and could be wrong 100%.

SlapAsksLiftOffers

Shlong please

SmoothJB

Cardiff Oncology Inc (NASDAQ:CRDF) Possible double bottom pattern. I think this stock has found support around the $10.3-$11 range and looks poised to post a bounce from here. I could see a 20-30% possible bounce up to $16 a share if it can close above $12.50

MoreMoney11

Not convinced on bull or bear side. Totally neutral right now. I need more confirmation but here is what I see. We had some decent buying by bulls @ $10.20 which is a critical support level . Bad news for bulls there wasn't any decent buying after that. In my opinion price will break down towards $6.20 -$5.50 range, but If we do show signs of buying pressure,...

RJLeo82

see chart for possible bounce spot, bad data smoked this CRDF

RJLeo82

see chart stop below x

NetWorthFocused

I like the repeat of this pattern from October. History of structure; RSI checked down/bounced on the bottom of the bull zone; similar break of counter trendline; reclaimed 8 & 21 EMA. I have a position.

Kaushik167

.

LeLaf

Bull Flag Descending volume PPS above 50MA and 200MA 200MA pointing up ATR pointing up If confirmed Target 1 = 5.12 Target 2 = 5.79 Target 3 = 6.43 Target 4 = 7.76

Alaa1990

Good Luck

PennyStock101

Cardiff Oncology, Inc. is a clinical-stage, precision cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan...